The primary focus of this Treatment Improvement Protocol (TIP) is the *in utero* exposure of infants to illicit drugs. *In utero* exposure to cocaine and opiates, especially heroin, is highlighted, and there is a brief discussion of methadone. Although the substantial crisis of *in utero* exposure to alcohol is discussed, it is not the focal concern of this TIP. In addition, this TIP highlights medical and psychosocial services for drug-exposed infants *up to 18 months of age* and their families. Concerns regarding older toddlers and children are mentioned, but they are not the TIP's focus.

**Contents**

What Is A TIP?

Consensus Panel

Chapter 1 - Introduction

  What is Covered in this TIP?

  Statement of the Problem

  The Impact of Drug Exposure on Infants

Chapter 2 - Medical Management of The Drug-Exposed Infant

  Alcohol Use in Pregnancy

  Diagnosis of *In Utero* Drug Exposure

  Medical Assessment of the Drug-Exposed Neonate

  *In Utero* Exposure To Opiates: Effects And Treatment

  *In Utero* Exposure To Cocaine: Effects And Treatment

  Promoting Positive Mother-Infant Interaction

  Discharging the Drug-Exposed Infant from the Hospital

Chapter 3 - Followup and Aftercare of Drug-Exposed Infants

  Early Interventions For Infants

  Interventions for Toddlers

  Transition to the Preschool Period

  Quality Assurance Checklist

  Training for Child-Oriented Professionals
Chapter 4 - Psychosocial Services for Drug-Exposed Infants and Their Families

Comprehensive Psychosocial Services

Treatment For Parents

Maternal Health Services

Mental Health Services for the Parents

Parental Educational/Vocational Services And Employment Assistance

Other Social Services

Helping Parents or Guardians Obtain Supportive Services

Keeping Families Intact

Referral to Child Protective Services

Followup of Infants In CPS or Foster Care

Assuring the Quality of Services For Infants in Foster Care

Chapter 5 - Ethical and Legal Guidelines

Assessment of Mothers and Infants for Drug Use / Drug Exposure

Reporting Laws And Laws Governing Confidentiality

Issues Arising During Postneonatal Followup

Training in Legal And Ethical Issues

Chapter 6 - Quality Assurance Guidelines

Documentation of Referral to Ensure Linkage

Compliance with Federal Guidelines For Confidentiality

Interagency Agreements

Other Important Areas for Monitoring

Appendix A - Resources

Appendix B - Sample Programs

Appendix C - Urine toxicology Guidelines

Appendix D - Description of IDEA

Appendix E - Family Service Plan

Appendix F - Medical Glossary

Appendix G - Cost Factors

Appendix H - Federal Resource Panel

Appendix I - Field Reviewers

References
This publication is part of the Substance Abuse Prevention and Treatment Block Grant technical assistance program. This publication was written under contract number ADM 270-91-0007 from CSAT. Al Getz, MSW; Anna Marsh, PhD; and Sandra Clunies, MS served as the CSAT government project officers. Lynne Bailey, Carolyn Davis, and Claudia Norris served as contractor writers.

The opinions expressed herein are the views of the consensus panel participants and do not reflect the official position of CSAT or any other part of the U.S. Department of Health and Human Services (DHHS). No official support or endorsement of CSAT or DHHS is intended or should be inferred. The guidelines proffered in this document should not be considered as substitutes for individualized patient care and treatment decisions.

Copyright Notice

Bookshelf ID: NBK64750   PMID: 22514857